Fusion Pharmaceuticals Financials

Based on the key indicators related to Fusion Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Fusion Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.
  
Understanding current and past Fusion Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Fusion Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Fusion Pharmaceuticals' assets may result in an increase in income on the income statement.

Fusion Pharmaceuticals Stock Summary

Fusion Pharmaceuticals competes with Bicycle Therapeutics, Relmada Therapeutics, RAPT Therapeutics, NewAmsterdam Pharma, and Bioatla. Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. Fusion Pharmaceuticals is traded on NASDAQ Exchange in the United States.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINCA36118A1003
Business Address270 Longwood Road
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.fusionpharma.com
Phone289 799 0891
CurrencyUSD - US Dollar

Fusion Pharmaceuticals Key Financial Ratios

Fusion Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Fusion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Fusion Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fusion Pharmaceuticals competition to find correlations between indicators driving Fusion Pharmaceuticals's intrinsic value. More Info.
JavaScript chart by amCharts 3.21.15HRMYSPROJANXBCYCPMVPGRCLFUSN -0.25-0.20-0.15-0.10-0.0500.050.100.15 -0.5-0.4-0.3-0.2-0.100.10.20.3
Fusion Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Fusion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Consideration for investing in Fusion Stock

If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments

Trending Assets

BCAB
Bioatla
0.31  -0.03  -8.82 
JANX
Janux Therapeutics
29.25  -0.97  -3.21 
NLTX
Neoleukin Therapeutics
0.00  0.00  0.00 
GRCL
Gracell Biotechnologies
0.00  0.00  0.00